Oculis Holding AG (NASDAQ:OCS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have been assigned an average recommendation of “Moderate Buy” from the five research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $41.00.

Several equities research analysts have recently weighed in on the company. HC Wainwright upped their price objective on Oculis from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Chardan Capital upped their price objective on Oculis from $33.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday, October 8th. Needham & Company LLC assumed coverage on Oculis in a research note on Wednesday, August 27th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th.

Oculis Trading Up 1.0%

Shares of OCS opened at $19.48 on Tuesday. Oculis has a 12-month low of $14.00 and a 12-month high of $23.08. The company has a quick ratio of 4.55, a current ratio of 4.55 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $850.50 million, a price-to-earnings ratio of -7.30 and a beta of 0.29. The stock’s 50-day moving average price is $18.73 and its 200 day moving average price is $18.55.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06). Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.14 million. As a group, research analysts predict that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

A number of large investors have recently bought and sold shares of OCS. Kestra Private Wealth Services LLC bought a new stake in Oculis during the 1st quarter worth approximately $234,000. Bosun Asset Management LLC bought a new stake in Oculis during the 2nd quarter worth approximately $378,000. Marshall Wace LLP bought a new stake in Oculis during the 2nd quarter worth approximately $393,000. Geode Capital Management LLC grew its position in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.